{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T18:10:47Z","timestamp":1775239847223,"version":"3.50.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1053\/j.seminhematol.2010.01.010","type":"journal-article","created":{"date-parts":[[2010,3,30]],"date-time":"2010-03-30T14:05:35Z","timestamp":1269957935000},"page":"170-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Rituximab in Autoimmune Hematologic Diseases: Not Just a Matter of B Cells"],"prefix":"10.1053","volume":"47","author":[{"given":"Roberto","family":"Stasi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.01.010_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/35100573","article-title":"From T to B and back again: positive feedback in systemic autoimmune disease","volume":"1","author":"Shlomchik","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.berh.2005.05.006","article-title":"New treatments for SLE: cell-depleting and anti-cytokine therapies","volume":"19","author":"Anolik","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/82717","article-title":"Reciprocal regulation of polarized cytokine production by effector B and T cells","volume":"1","author":"Harris","year":"2000","journal-title":"Nat Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib4","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1146\/annurev.immunol.22.012703.104538","article-title":"Cell biology of antigen processing in vitro and in vivo","volume":"23","author":"Trombetta","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib5","doi-asserted-by":"crossref","first-page":"5558","DOI":"10.4049\/jimmunol.165.10.5558","article-title":"A critical role for B cells in the development of memory CD4 cells","volume":"165","author":"Linton","year":"2000","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/157488708783330495","article-title":"Pharmacokinetic properties of rituximab","volume":"3","author":"Rodriguez","year":"2008","journal-title":"Rev Recent Clin Trials"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib7","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1084\/jem.20021290","article-title":"Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo","volume":"197","author":"Linton","year":"2003","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib8","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","article-title":"Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib9","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","article-title":"B cells move to centre stage: novel opportunities for autoimmune disease treatment","volume":"5","author":"Browning","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1600-065X.2008.00646.x","article-title":"B-lymphocyte contributions to human autoimmune disease","volume":"223","author":"Yanaba","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1084\/jem.192.4.475","article-title":"B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation","volume":"192","author":"Moulin","year":"2000","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib12","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.4049\/jimmunol.174.9.5720","article-title":"Adaptive immune responses are dispensable for isolated lymphoid follicle formation: antigen-naive, lymphotoxin-sufficient B lymphocytes drive the formation of mature isolated lymphoid follicles","volume":"174","author":"McDonald","year":"2005","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib13","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib14","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib15","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib16","first-page":"887","article-title":"Clinical outcome following B cell depletion therapy in eight patients with refractory idiopathic inflammatory myopathy","volume":"26","author":"Sultan","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib17","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/rheumatology\/kel148","article-title":"Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy","volume":"46","author":"Leandro","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib19","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1365-2141.2004.04889.x","article-title":"The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura","volume":"125","author":"Cooper","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib22","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood-2002-11-3547","article-title":"Rituximab for the treatment of refractory autoimmune hemolytic anemia in children","volume":"101","author":"Zecca","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib23","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2006.06448.x","article-title":"Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13","volume":"136","author":"Scully","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib24","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib25","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/ndt\/gfh599","article-title":"Effective therapeutic use of rituximab in refractory Wegener's granulomatosis","volume":"20","author":"Ferraro","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib26","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kel098","article-title":"Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab","volume":"45","author":"Stasi","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib27","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib29","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1172\/JCI113076","article-title":"B lymphocyte reconstitution after human bone marrow transplantation","volume":"80","author":"Antin","year":"1987","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib30","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.1002\/art.24141","article-title":"Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab","volume":"58","author":"Palanichamy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib31","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/intimm\/2.6.487","article-title":"Persistence of memory B cells in mice deprived of T cell help","volume":"2","author":"Vieira","year":"1990","journal-title":"Int Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib32","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1084\/jem.20042251","article-title":"Defective B cell tolerance checkpoints in systemic lupus erythematosus","volume":"201","author":"Yurasov","year":"2005","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib33","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.189.10.1639","article-title":"A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus","volume":"189","author":"Chan","year":"1999","journal-title":"J Exp Med"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib34","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","article-title":"Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura","volume":"110","author":"Stasi","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/nrrheum.2009.141","article-title":"B-cell-directed therapies for autoimmune disease","author":"Dorner","year":"2009","journal-title":"Nat Rev Rheumatol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib36","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib37","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann Neurol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1874312900802010081","article-title":"Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"2","author":"Feuchtenberger","year":"2008","journal-title":"Open Rheumatol J"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1600-065X.2008.00627.x","article-title":"Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis","volume":"223","author":"Silverman","year":"2008","journal-title":"Immunol Rev"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07054.x","article-title":"Rituximab in the treatment of autoimmune haematological disorders","volume":"141","author":"Garvey","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib41","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.intimp.2008.10.004","article-title":"A review of the current use of rituximab in autoimmune diseases","volume":"9","author":"Gurcan","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib42","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ejim.2007.08.012","article-title":"New treatment options for immune-mediated hematological disorders","volume":"19","author":"Dierickx","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1160\/TH07-08-0513","article-title":"Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management","volume":"99","author":"Stasi","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib44","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib45","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/MOH.0b013e3282c8ca50","article-title":"Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?","volume":"14","author":"Cooper","year":"2007","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncprheum0424","article-title":"Drug insight: the mechanism of action of rituximab in autoimmune disease--the immune complex decoy hypothesis","volume":"3","author":"Taylor","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib47","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood-2008-01-131029","article-title":"Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study","volume":"112","author":"Godeau","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/pbc.21757","article-title":"One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab","volume":"52","author":"Mueller","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib49","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2005-08-3518","article-title":"Prospective phase 1\/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura","volume":"107","author":"Bennett","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib50","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jpeds.2004.09.004","article-title":"Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment","volume":"146","author":"Wang","year":"2005","journal-title":"J Pediatr"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib51","first-page":"281","article-title":"Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood","volume":"90","author":"Taube","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib52","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3324\/haematol.11709","article-title":"Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults","volume":"92","author":"Provan","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib53","doi-asserted-by":"crossref","first-page":"930","DOI":"10.3324\/haematol.12206","article-title":"Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura","volume":"93","author":"Zaja","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V112.11.1.1","article-title":"A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up [abstract]","volume":"112","author":"Zaja","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib55","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/blood-2009-06-225565","article-title":"International consensus report on the investigation and management of primary immune thrombocytopenia","volume":"115","author":"Provan","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib56","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ajh.10062","article-title":"Autoimmune hemolytic anemia","volume":"69","author":"Gehrs","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib57","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.4065\/78.11.1340","article-title":"Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome","volume":"78","author":"Shanafelt","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib58","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1600-0609.2007.00861.x","article-title":"Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients","volume":"79","author":"D'Arena","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib59","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.20665","article-title":"Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia","volume":"81","author":"D'Arena","year":"2006","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib60","first-page":"1273","article-title":"Rituximab in the treatment of refractory autoimmune cytopenias in adults","volume":"90","author":"Narat","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib61","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","article-title":"Treatment of childhood autoimmune haemolytic anaemia with rituximab","volume":"358","author":"Quartier","year":"2001","journal-title":"Lancet"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib62","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/sj.leu.2402676","article-title":"Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia","volume":"16","author":"Gupta","year":"2002","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib63","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/pbc.21264","article-title":"Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias","volume":"50","author":"Rao","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib64","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ajh.21341","article-title":"Efficacy and safety of rituximab in adults' warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases","volume":"84","author":"Bussone","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib65","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib66","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/10428190500286481","article-title":"Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients","volume":"47","author":"Sch\u00f6llkopf","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib67","first-page":"460","article-title":"Primary chronic cold agglutinin disease: a population based clinical study of 86 patients","volume":"91","author":"Berentsen","year":"2006","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib68","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1111\/j.1537-2995.2007.01414.x","article-title":"Rituximab as successful therapy in a patient with refractory paroxysmal cold hemoglobinuria","volume":"47","author":"Koppel","year":"2007","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib69","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1056\/NEJMcp053024","article-title":"Clinical practice","volume":"354","author":"George","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2008-02-078170","article-title":"Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura","volume":"112","author":"Sadler","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib71","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3324\/haematol.12701","article-title":"Acquired thrombotic thrombocytopenic purpura: ADAMTS13 activity, anti-ADAMTS13 autoantibodies and risk of recurrent disease","volume":"93","author":"Lammle","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib72","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2005-03-0848","article-title":"Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases","volume":"106","author":"Fakhouri","year":"2005","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib73","first-page":"965","article-title":"Timing of plasma exchange and rituximab for the treatment of thrombotic thrombocytopenic purpura","volume":"126","author":"Boctor","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib74","first-page":"210","article-title":"Efficacy of rituximab and concurrent plasma exchange in the treatment of thrombotic thrombocytopenic purpura","volume":"4","author":"Hull","year":"2006","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib75","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1309\/RLNMJ01WBJRNLH03","article-title":"Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP","volume":"125","author":"Darabi","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib76","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/j.1538-7836.2004.00678.x","article-title":"Rituximab in patients with refractory thrombotic thrombocytopenic purpura","volume":"2","author":"Sallah","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib77","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s00277-004-0964-6","article-title":"Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura","volume":"84","author":"Reddy","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib78","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1160\/TH06-09-0499","article-title":"Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia","volume":"97","author":"Heidel","year":"2007","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib79","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ajh.21439","article-title":"Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature","volume":"84","author":"Ling","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib80","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1600-0609.2009.01292.x","article-title":"Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature","volume":"83","author":"Elliott","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib81","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1160\/TH07-12-0753","article-title":"Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies","volume":"101","author":"Bresin","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib82","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib83","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/j.1537-2995.2005.00560.x","article-title":"Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab","volume":"45","author":"Millward","year":"2005","journal-title":"Transfusion"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib84","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2006-11-059469","article-title":"Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib85","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0609.2009.01215.x","article-title":"Rapid infusion of rituximab over 60 min","volume":"82","author":"Tuthill","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib86","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/ajh.21203","article-title":"Attenuated doses of rituximab for the treatment of adults with autoimmune cytopenias","volume":"83","author":"D'Arena","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib87","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib88","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib89","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","author":"Yeo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib90","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.21022","article-title":"Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy","volume":"83","author":"Ennishi","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib91","first-page":"430","article-title":"Serum sickness following treatment with rituximab","volume":"34","author":"Todd","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib92","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"10.1053\/j.seminhematol.2010.01.010_bib93","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s11912-008-0064-1","article-title":"Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma","volume":"10","author":"Sikder","year":"2008","journal-title":"Curr Oncol Rep"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:56Z","timestamp":1758522056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0037196310000119"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.010","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab in Autoimmune Hematologic Diseases: Not Just a Matter of B Cells","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}